Teresa de Leon’s Post

𝗘𝘅𝗰𝗹𝘂𝘀𝗶𝘃𝗲 𝗦𝗽𝗲𝗮𝗸𝗲𝗿 𝗜𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄𝘀 Amit Sharma and Samvel Gasparyan discussed the transformations in the kidney disease treatment landscape over the past year, emphasizing notable breakthroughs and persistent obstacles faced by the #CKD field. You can read the full interviews here: https://ter.li/media-hub Join Amit and Samvel, alongside 200+ biopharma stakeholders, KOLs and regulators at the definitive 𝟲𝘁𝗵 𝗖𝗞𝗗 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗦𝘂𝗺𝗺𝗶𝘁 to collaboratively advance the frontier of more personalized, efficacious therapies for rare and common kidney disease.

Article | What’s hot in molecular diagnostics and where it’s going Staying informed on the latest trends in molecular-diagnostics is key to staying ahead in the fight against disease. Read our blog to find out what’s hot in molecular-diagnostics, and where we are taking it. https://lnkd.in/dUHXesMb #diagnostics #immunodiagnostics #lifesciences #biopharma

ICT Spring 2024 is now live! ☀️ Featuring insights in Decentralised Clinical Trials, Orphan Drug and Rare Disease Trials, and much more! Read here: https://bit.ly/3URlpxX #ClinicalTrials #decentralisedclinicaltrials #rarediseases #orphandrugs #pharmaceuticalindustry

Disease registries are a valuable source of real-world data across the drug development process. In our latest blog, we share some insights from our experiences with building disease registries. https://bit.ly/3QVJdxq #registries #RWD

This great read outlines the role of RWE in clinical development. For geneticists operating in the age of growing multi-omics repositories, RWE presents a platform to fine-tune genotype-phenotype matching. Thanks Tsitsi Monera-Penduka, PhD!

Last chance to register for tomorrow’s “A New Dimension: Biopharma Market Dynamics at the Disease Level” webinar. Together we will explore sales insights by disease, looking at volume and value terms, molecules and product growth trends and key disease areas in #generics. Let’s explore the disease trends and forecasts together, using the most granular information available. https://bit.ly/3RHDAFf

ICT Spring 2024 is now live! ☀️ Featuring insights in Decentralised Clinical Trials, Orphan Drug and Rare Disease Trials, and much more! Read here: https://bit.ly/3URlpxX #ClinicalTrials #decentralisedclinicaltrials #rarediseases #orphandrugs #pharmaceuticalindustry

Did you know that there are more than 7,000 rare diseases, and that number is steadily growing? Here are some fast facts on #RareDisease:    🔸 Rare disease affects between 25 and 30 million people in the U.S.  🔸 Around 95% of rare diseases have no approved treatment  🔸 Roughly 72% of rare diseases are genetic  🔸 One in 15 children is born with a rare disease    Visit https://lnkd.in/gvQEJXzu to learn more about Sentynl’s work in the rare disease space.    #SentynlSeeks  

Q2 Business Update: View Kiora's latest presentation detailing our sharpened focus on orphan retinal disease including, #retinitispigmentosa, #Stargardts, & #Choroideremia (see presentation at top of IR homepage) https://lnkd.in/eB-8-BzE  #sightloss  $KPRX #RetinalDystrophy